Assertio postpones tender offer commencement to May 8 By Investing.com

Assertio agreed to postpone its tender offer to May 8, 2026, while its amended merger agreement with Garda Therapeutics values the company at $21.80 per share in cash, or $153.2 million, a 21.1% increase from the original offer. The stock trades at $21.61, leaving less than a 1% arbitrage spread, and has risen 138% year-to-date near its 52-week high. Separately, Cosette completed the purchase of U.S. sales and distribution rights for seven Assertio products for $48.9 million, further reshaping the company’s portfolio.

Analysis

The clean read is that ASRT is no longer a directional equity story; it is a near-term event-driven instrument with the economics dominated by closing certainty, not fundamentals. When a deal is already tight to price, the real edge shifts to timing and funding risk: every extension increases the probability of a mechanical de-risking trade, but also raises the odds of a nuisance break if financing, approvals, or note-holder coordination get messy. In this setup, the seller base matters more than the business model — index and arb funds can pin the stock, but any deterioration in process quality can widen the spread quickly because there is almost no cushion left.

The second-order beneficiary is not the acquirer per se, but the market for asset carve-outs in small-cap healthcare. The separate monetization of product rights signals that the remaining entity was being stripped to maximize certainty and price, which can pressure similar portfolios to accelerate divestitures rather than pursue full-company M&A. That usually compresses timelines for peers with non-core assets, while reducing optionality for standalone holders who were hoping for a broader strategic rerating.

The main contrarian point is that the upside is probably capped even if the deal closes cleanly, while the downside remains asymmetric if the process slips. With a spread this narrow, the market is effectively pricing a very high probability of completion; the hidden risk is not valuation, but calendar drift and technical unwind if tender timing changes again. Over the next few weeks, the key catalyst is not headline price action but whether the tender becomes an unambiguous all-in arb or remains a stale, low-carry stub with poor liquidity.

AMD in the headline appears to be noise and should not be conflated with the ASRT setup; any cross-asset read-through is likely zero. For healthcare event books, this is more about capital allocation discipline than stock selection: use it to recycle capital out of crowded, low-spread arb names and into wider-spread situations where process risk is underpriced.

Key Decisions for Investors

• Keep ASRT as a minimal exposure / cash-equivalent arb position only if already owned; do not add at sub-1% spread unless there is a clearly higher annualized carry than alternative special situations.
• If long ASRT, tighten risk around the new tender date and consider selling against strength into any pre-close convergence; expected reward is limited to the remaining spread, while a process miss can erase months of carry.
• Screen for similar healthcare microcap takeouts with 2%+ spreads and stronger financing visibility; rotate capital from ASRT into wider-spread names where the annualized return can be 2-3x higher for comparable event risk.
• Avoid initiating any long/short pair around ASRT common versus peers — the stock is too close to cash value for the trade to be a true fundamental hedge, and borrow/technical dynamics can dominate.